Avadel settled with Jazz Pharmaceuticals, clearing legal hurdles for Alkermes' $20/share acquisition. Click to read my update ...

Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...

Alkermes plc ALKS announced that it has entered into a definitive agreement to acquire Ireland-based Avadel Pharmaceuticals ...

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The ...

CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

Contributed by Tai-ping Sun; received May 6, 2025; accepted July 7, 2025; reviewed by Huilin Li, Makoto Matsuoka, and Claus Schwechheimer ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

Icahn Genomics Institute, Precision Immunology Institute, Department of Immunology and Immunotherapy, Department of Oncological Sciences, Tisch Cancer Institute, Biomedical Engineering and Imaging ...